Table 9.

Decitabine in clinical trials.

Drug	Conditions	Status	NCT number	Phases
Decitabine	MDS|CML	Completed	NCT00067808	Phase 2
Decitabine	Thalassemia	Completed	NCT00661726	Phase 2
Decitabine	Lymphoma, intestinal neoplasms	Completed	NCT00089089	Phase 1
Decitabine	AML	Completed	NCT00866073	Phase 2
Decitabine	AML, MDS	Completed	NCT00760084	Phase 2
Decitabine	MDS, CML	Terminated	NCT00113321	Phase 2
Decitabine	Leukemia	Completed	NCT01378416	Phase 1
Decitabine	CML	Completed	NCT01098084	Phase 2
Decitabine	AML	Completed	NCT00398983	Phase 2|3
Decitabine	MDS	Completed	NCT00043381	Phase 3
Decitabine	AML	Completed	NCT00538876	Phase 1
Decitabine	MDS	Terminated	NCT00282399	Phase 1|2
Decitabine	CML	Completed	NCT00042003	Phase 2
Decitabine	CML	Completed	NCT00042016	Phase 2
Decitabine	CML	Completed	NCT00041990	Phase 2
Decitabine	MDS	Completed	NCT00260065	Phase 2
Decitabine	MDS	Completed	NCT01041846	N/A
Decitabine	MDS	Completed	NCT00796003	Phase 1
Decitabine	AML	Completed	NCT00358644	Phase 2
Decitabine	Leukemia, MDS	Completed	NCT00003361	Phase 2
Decitabine	Leukemia, MDS	Completed	NCT00049582	Phase 1
Decitabine	MDS, secondary myelofibrosis	Terminated	NCT00630994	Phase 2
Decitabine	Bladder cancer, breast cancer, melanoma	Completed	NCT00030615	Phase 1
Decitabine	Esophageal, lung cancer, malignant mesothelioma	Completed	NCT00019825	Phase 1
Decitabine	Leukemia	Completed	NCT00042796	Phase 1
Decitabine	MDS, leukemia, lymphoma, MM	Completed	NCT00002980	Phase 1